Document Detail


Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
MedLine Citation:
PMID:  11337315     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To determine the effects of a saw palmetto herbal blend (SPHB) compared with finasteride on prostatic tissue androgen levels and to evaluate needle biopsies as a source of tissue for such determinations. METHODS: Prostate levels of testosterone and dihydrotestosterone (DHT) were measured on 5 to 10-mg biopsy specimens (18-gauge needle cores) in three groups of men with symptomatic benign prostatic hyperplasia: 15 men receiving chronic finasteride therapy versus 7 untreated controls; 4 men undergoing prostate adenomectomy to determine sampling variability (10 specimens each); and 40 men participating in a 6-month randomized trial of SPHB versus placebo, before and after treatment. RESULTS: Prostatic tissue DHT levels were found to be several times higher than the levels of testosterone (5.01 versus 1.51 ng/g), that ratio becoming reversed (1.05 versus 3.63 ng/g) with chronic finasteride therapy. The finasteride effect was statistically significant for both androgens (P <0.01), and little overlap of individual values between finasteride-treated and control patients was seen. In the randomized trial, tissue DHT levels were reduced by 32% from 6.49 to 4.40 ng/g in the SPHB group (P <0.005), with no significant change in the placebo group. CONCLUSIONS: For control versus finasteride-treated men, the tissue androgen values obtained with needle biopsy specimens were similar-both for absolute values and the percentage of change-to those previously reported using surgically excised volumes of prostatic tissue. The quantification of prostatic androgens by assay of needle biopsies is thus feasible and offers the possibility of serial studies in individual patients. The SPHB-induced suppression of prostatic DHT levels, modest but significant in a randomized trial, lends an element of support to the hypothesis that inhibition of the enzyme 5-alpha reductase is a mechanism of action of this substance.
Authors:
L S Marks; D L Hess; F J Dorey; M Luz Macairan; P B Cruz Santos; V E Tyler
Related Documents :
5075225 - Androgen dynamics in vitro in the human prostate gland. effect of oestradiol-17 .
16467405 - Matriptase activation and shedding with hai-1 is induced by steroid sex hormones in hum...
17007995 - Antiandrogens in the treatment of prostate cancer.
16986005 - Emerging pharmacologic therapies for prostate cancer.
17676035 - Lkb1 modulates lung cancer differentiation and metastasis.
25011545 - Myofibroblastic stromal reaction and lymph node status in invasive breast carcinoma: po...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Urology     Volume:  57     ISSN:  1527-9995     ISO Abbreviation:  Urology     Publication Date:  2001 May 
Date Detail:
Created Date:  2001-05-04     Completed Date:  2001-06-07     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  999-1005     Citation Subset:  IM    
Affiliation:
Urological Sciences Research Foundation, Culver City, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Androgen Antagonists / pharmacology*,  therapeutic use
Biopsy, Needle / statistics & numerical data
Dihydrotestosterone / analysis*
Enzyme Inhibitors / pharmacology*,  therapeutic use
Finasteride / pharmacology*,  therapeutic use
Humans
Male
Middle Aged
Placebos
Plant Extracts / pharmacology*,  therapeutic use
Prostate / chemistry*,  drug effects*,  pathology
Prostatic Hyperplasia / drug therapy*,  pathology
Serenoa
Testosterone / analysis*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
HD18185/HD/NICHD NIH HHS; RR00163/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Androgen Antagonists; 0/Enzyme Inhibitors; 0/Permixon; 0/Placebos; 0/Plant Extracts; 521-18-6/Dihydrotestosterone; 58-22-0/Testosterone; 98319-26-7/Finasteride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased intracellular doxorubicin by anti-FAS monoclonal antibody: a mechanism that enhances the c...
Next Document:  Reverse transcriptase-polymerase chain reaction for prostate-specific antigen in the molecular stagi...